Get the Stockscreener App
1.61
8.05%
0.12
Celularity Inc stock is traded at $1.61, with a volume of 79,946.
It is up +8.05% in the last 24 hours and down -11.54% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
See More
Previous Close:
$1.49
Open:
$1.5
24h Volume:
79,946
Relative Volume:
0.56
Market Cap:
$39.04M
Revenue:
$48.20M
Net Income/Loss:
$-35.05M
P/E Ratio:
-1.0272
EPS:
-1.5673
Net Cash Flow:
$-13.02M
1W Performance:
-1.83%
1M Performance:
-11.54%
6M Performance:
-29.88%
1Y Performance:
-49.84%
1-Day Range:
$1.50
$1.7699
1-Week Range:
$1.47
$1.7778
52-Week Range:
$1.06
$5.22
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.61 | 39.04M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.42 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.85 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.65 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.97 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Celularity faces Nasdaq delisting over late filing By Investing.com - Investing.com South Africa
Celularity faces Nasdaq delisting over late filing - Investing.com
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products - The Manila Times
CMS Extends Medicare Coverage for Wound Care Products: Major Win for Skin Substitute Market - Stock Titan
Revolutionary NK Cell Therapy Shows Promise in Cancer Treatment: New Research Reveals - Stock Titan
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology - The Globe and Mail
Celularity Delays Yearly Report Filing Amid Financial Challenges - TipRanks
Celularity extends debt maturity, issues stock to investor By Investing.com - Investing.com Australia
Celularity enters into standby equity purchase agreement with Ya Ii Pn -March 21, 2025 at 04:39 pm EDT - MarketScreener
Celularity enters into standby equity purchase agreement with Ya Ii Pn - TradingView
Robust Growth in Regenerative Placental Cell Therapy Market - openPR.com
Celularity receives FDA TRG recommendation letters for Natalin, Acelagraft - MSN
CELU Stock Touches 52-Week Low at $1.29 Amid Market Challenges - Investing.com Australia
CELU Stock Touches 52-Week Low at $1.29 Amid Market Challenges By Investing.com - Investing.com South Africa
Celularity Enters Strategic Collaboration Agreement with BlueSphere Bio to Support Cell Therapy Manufacturing - Defense World
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products - The Manila Times
Celularity Secures Crucial FDA Pathway for Wound Care ProductsCan They Capture Share of $810M Market? - StockTitan
Celularity inks manufacturing deal with BlueSphere Bio By Investing.com - Investing.com Australia
Celularity inks manufacturing deal with BlueSphere Bio - Investing.com
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company - The Manila Times
Can This New Cell Therapy Manufacturing Deal Transform Celularity's Revenue Potential? - StockTitan
Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry - Simply Wall St
Celularity Inc. Extends Loan Agreements with Resorts World Inc and C.V. Starr & Co. - Defense World
SEC Form FWP filed by Celularity Inc. - Quantisnow
Celularity Inc (CELU) Stock: Analyzing the Market Value - The News Heater
Celularity Inc (CELU) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Placental Stem Cell Therapy Solution Market Size And Booming - openPR
Celularity files to sell 6.52M shares of Class A common stock, warrants - MSN
Celularity cancels material agreement with investor - MSN
Celularity amends warrant terms, secures $2.46 million funding By Investing.com - Investing.com Canada
Celularity amends warrant terms, secures $2.46 million funding - Investing.com India
MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs - The Manila Times
Celularity cancels material agreement with investor By Investing.com - Investing.com
Celularity Faces Challenges as Agreement Expires - TipRanks
Celularity Inc. (NASDAQ:CELU) Short Interest Up 7.1% in December - Defense World
Celularity (NASDAQ:CELU) Shares Down 0.5% – Here’s What Happened - Defense World
Amniotic Products Global Industry Report 2025: Growth in Regenerative Medicine Propels the Use of Amniotic Products in Tissue Repair and Healing - GlobeNewswire Inc.
**Celularity Inc. Holds Annual Meeting and Reports Voting Results** - Defense World
CELUCelularity Inc. Latest Stock News & Market Updates - StockTitan
Celularity announces resolution of Nasdaq listing compliance matter - Nasdaq
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter - The Manila Times
Celularity Restores Nasdaq Compliance After Major Financial Reporting Overhaul - StockTitan
Celularity reports Q3 EPS (73c) vs. ($4.98) last year - MSN
Celularity Gets Back On Track With Quarterly Submissions; Q3 Revenue Jump 145% - Nasdaq
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023 - The Manila Times
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
21.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):